Loading clinical trials...
Loading clinical trials...
A Double-Blind, Phase III, Randomised Study to Compare the Efficacy and Safety of Oral Azacitidine (CC-486) Versus Placebo in Subjects With Acute Myeloid Leukaemia or Myelodysplastic Syndromes as Maintenance After Allogeneic Haematopoietic Stem Cell Transplantation
Conditions
Interventions
Oral azacitidine
Matched placebo
Locations
20
United Kingdom
The Queen Elizabeth Hospital
Birmingham, United Kingdom
University Hospital Bristol
Bristol, United Kingdom
Addenbrooke's Hospital
Cambridge, United Kingdom
University Hospital of Wales
Cardiff, United Kingdom
Queen Elizabeth University Hospital
Glasgow, United Kingdom
St. James's University Hospital
Leeds, United Kingdom
Start Date
June 14, 2019
Primary Completion Date
April 1, 2025
Completion Date
April 1, 2025
Last Updated
May 14, 2024
NCT06285890
NCT06220162
NCT04065399
NCT06994676
NCT06484062
NCT04628026
Lead Sponsor
University of Birmingham
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions